EP1945190A1 - Sprudelnde metformin-zusammensetzung und daraus hergestellte tabletten und granulate - Google Patents

Sprudelnde metformin-zusammensetzung und daraus hergestellte tabletten und granulate

Info

Publication number
EP1945190A1
EP1945190A1 EP05789610A EP05789610A EP1945190A1 EP 1945190 A1 EP1945190 A1 EP 1945190A1 EP 05789610 A EP05789610 A EP 05789610A EP 05789610 A EP05789610 A EP 05789610A EP 1945190 A1 EP1945190 A1 EP 1945190A1
Authority
EP
European Patent Office
Prior art keywords
effervescent
composition according
acid
component
carbonate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP05789610A
Other languages
English (en)
French (fr)
Inventor
Franz HÄUSLER
Till RÖHRICH
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Swissco Devcelopment AG
Original Assignee
Swissco Devcelopment AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Swissco Devcelopment AG filed Critical Swissco Devcelopment AG
Publication of EP1945190A1 publication Critical patent/EP1945190A1/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)

Definitions

  • the present invention relates to a composition containing at least one pharmaceutically acceptable salt of metformin that effervesces when added to water, and to tablets and granules obtained therefrom.
  • the invention also relates to a process for preparing said composition as well as to processes for making said tablets and granules. More specifically, the invention is directed to metformin hydrochloride compositions and tablets and granules made therefrom.
  • a water-soluble tablet that includes a pharmaceutically acceptable acceptable salt of metformin and dissolves to form a clear aqueous solution is disclosed in WO 2004/082664.
  • the conditions in which such a tablet dissolves are not indicated in that International patent application.
  • the data concerning the hardness show that such a tablet is relatively soft, which makes it difficult to be packaged. As such a tablet is fragile, it can be easily broken upon extraction from the packaging. Further, the shell-life of that tablet is relatively short.
  • the dissolution in only 30 ml of water gives a high concentration of the active ingredient, which imparts a strong unpleasant taste to the solution, especially when the active ingredient is metformin hydrochloride.
  • Metformin hydrochloride is an orally-administered antihyperglycemic agent, used in the management of non-insulin-dependent (type 2) diabetes mellitus, generally sold in tablets containing 500 mg, 850 mg and 1000 mg and available from many sources. For instance, in the United States and elsewhere it is sold by Bristol-Myers Squibb as Glucophage®. Glucophage® tablets have a core made of metformin hydrochloride, povidone and magnesium stearate, which is film-coated. From Ranbaxy Pharmaceuticals, Inc. RIOMET®, an oral solution is available containing 500 mg of metformin hydrochloride per 5 ml.
  • a high percentage of patients suffering from type 2 diabetes are elderly people showing a relatively high incidence of dysphagia. This means that those patients are unable to swallow tablets or have at least difficulties in doing so.
  • metformin this problem becomes even more relevant since the medication has normally to be taken lifelong day by day and the tablets are quite big due to the high dose of 500-1000 mg.
  • oral metformin hydrochloride tablets besides the active drug, further excipients are needed such as binders and lubricants for technical reasons. Furthermore functional excipients are needed to modify the disintegration of the tablets and the release of the drug from the dosage form.
  • metformin hydrochloride a tablet comprising 1000 mg of metformin hydrochloride would need to have a size of 19 mm x 10.5 mm (Glucophage® 1000 mg tablets) or more and would be very difficult to swallow. For this reason, metformin hydrochloride tablets are not suitable for a significant number of patients.
  • an effervescent tablet or granule composition of at least one metformin salt, particularly metformin hydrochloride combining the advantages of a tablet or granule form, such as accurate dose, high stability, easy to carry, with the advantages of a liquid form, such as easy to swallow, and to avoid the disadvantages of both dosage forms.
  • a further object is to provide an effervescent tablet with a reasonable disintegration time in water of less than three minutes and with a palatable taste of the resulting solution.
  • a third object is to provide a sodium-free effervescent tablet, since a high daily sodium intake is contraindicated in some diseases which are frequently correlated to the diabetes type 2 disease. This feature is highly advantageous for the composition of a generic drug.
  • the invention may be summarized in the following items 1-23 :
  • An effervescent composition of metformin comprising:
  • weight ratio of said acid compound or acid salt (b) to said alkaline effervescing compound (c) is greater than 2 : 1 , preferably greater than 3 : 1.
  • component (b) is an acid compound selected from the group consisting of citric acid, tartaric acid, malic acid, fumaric acid, adipic acid, succinic acid, acid anhydrides and their mixtures.
  • effervescent composition according to any one of the items 1- 4, wherein the component (c) is selected from the group consisting of carbonate salts, bicarbonate salts and mixtures thereof.
  • component (d) is a polymer binder, a sugar, a soluble starch derivative, an alcohol sugar or a mixture thereof.
  • the effervescent composition according to item 9 wherein the component (d) is an aqueous solution of a polymer binder.
  • the polymer binder is selected from the group consisting of polyethylene glycol, polyvinylpyrrolidone and their mixtures.
  • effervescent composition according to any one of the items 1-10, wherein the component (d) is an aqueous solution of sorbitol, mannitol or their mixtures.
  • effervescent composition according to any one of the items 1-12, wherein the component (a) is a pharmaceutically acceptable salt of metformin selected in the group consisting of phosphate, sulfate, hydrochloride, salicylate, maleate, benzoate, ethanedisulfonate, fumarate, glycolate, salts of dibasic acids, fumarate, succinate and combinations of two or more of these salts.
  • the component (a) is a pharmaceutically acceptable salt of metformin selected in the group consisting of phosphate, sulfate, hydrochloride, salicylate, maleate, benzoate, ethanedisulfonate, fumarate, glycolate, salts of dibasic acids, fumarate, succinate and combinations of two or more of these salts.
  • component (a) is present in an amount of from 10% to 30% by weight of the composition.
  • Tablets or granules comprising the effervescent composition according to any one of the items 1 -18.
  • a process for making effervescent tablets comprising the direct compression of an effervescent composition according to any one of the items 1-18 to form said effervescent tablets.
  • a process for making effervescent granules comprising the granulation of an effervescent composition according to any one of the items 1- 18 to form said effervescent granules.
  • composition of the invention may be in the form of a powder.
  • the tablets and granules obtained from the effervescent composition of the invention guarantee a rapid dissolution and satisfactory taste properties and which are stable under pharmaceutical test conditions both in tubes with desiccants and in aluminium strip packs.
  • the component (a) of the composition, tablet or granules of the invention is a pharmaceutically acceptable salt of metformin or a combination of pharmaceutically acceptable salts of metformin.
  • compositions, tablet or granules of the invention may include phosphate, sulfate, hydrochloride, salicylate, maleate, benzoate, ethanedisulfonate, fumarate, glycolate, salts of dibasic acids, fumarate, succinate and combinations of two or more of these salts.
  • Metformin hydrochloride is preferred and that is why the invention will now be described with reference to metformin hydrochloride, although it must not be considered to be limited to the use of metformin hydrochloride.
  • Metformin hydrochloride is used as oral antihyperglycemic drug for the management of type 2 diabetes.
  • Metformin hydrochloride N 1 N- dimethylimidodicarbonimidic diamide hydrochloride
  • Metformin hydrochloride is a white to off-white crystalline compound with a molecular formula of C4H11N 5 • HCI and a molecular weight of 165.63 g.
  • Metformin hydrochloride is freely soluble in water and practically insoluble in acetone, ether, and chloroform.
  • the pKa of metformin is 12.4; the pH of a 1% aqueous solution of meformin hydrochloride is 6.68.
  • the metformin hydrochloride compositions of the invention are characterized by a surprisingly high amount of an acid compound and by a surprisingly small amount of an alkaline effervescing compound.
  • metformin hydrochloride The physico-chemical properties of metformin hydrochloride indicate that the drug should be quite suitable for effervescent compositions, especially effervescent tablet compositions.
  • the substance characteristics which are relevant for the suitability for effervescent compositions are similar to those of paracetamol or look even a little better for metformin hydrochloride. Since paracetamol is a substance widely used in effervescent tablets, also metformin hydrochloride was not expected to cause major composition problems.
  • Table A presents a comparison of both drug substances:
  • Any effervescent composition in any dosage form essentially consists of an alkaline component which is able to provide gaseous CO 2 when it gets in contact with an acid component which is able set free the CO2 gas from the alkaline component.
  • the acid component of the composition can be any suitable acid for effervescent compositions.
  • the acid is an organic or mineral acid that is safe for consumption and which provides effective and rapid effervescent disintegration upon contact with water and the alkaline effervescent compound.
  • the acid may be selected from the group consisting of citric acid, tartaric acid, malic acid, fumaric acid, adipic acid, succinic acid, acid anhydrides, related organic acids and their mixtures.
  • the acid is citric acid, especially anhydrous citric acid, or tartaric acid.
  • the acid salt of the composition can be any suitable acid salt or any mixture of suitable salts.
  • suitable acid salt include disodium dihydrogen pyrophosphate, acid citrate salts including mono sodium citrate, and other salts of related organic acids. Combinations thereof are possible.
  • the acid salt is a salt of citric acid or tartaric acid, especially monosodium citrate or monosodium tartarate.
  • the alkaline component can be any suitable alkaline effervescent compound, and typically it is an inorganic base (e.g., an alkali metal carbonate) that is safe for human consumption and provides an effective and rapid effervescent disintegration upon contact with water and the acid compound.
  • the alkaline effervescing compound may be selected from the group consisting of carbonate salts, bicarbonate salts, and mixtures thereof.
  • the alkaline compound is sodium bicarbonate, sodium carbonate anhydrous, potassium carbonate, and potassium bicarbonate, sodium glycine carbonate, calcium carbonate, L-lysine carbonate, arginine carbonate, and combinations thereof.
  • the alkaline effervescing compound is sodium bicarbonate, potassium bicarbonate, sodium carbonate or mixtures thereof.
  • citric acid At a pH of 4.4, more than 50 % of the citric acid is used to neutralize the metformin hydrochloride drug substance and is not available to react with the carbonate and to set free CO2 gas from the carbonate.
  • the characteristic reaction of any effervescent composition is the reaction between an acidic compound and a carbonate salt forming CO 2 gas:
  • the CO 2 gas is responsible for the creation of the characteristic effervescent bubbles and for the disintegration and the subsequent dissolution of the effervescent tablet. Therefore any effervescent tablet needs to contain a sufficient absolute amount of carbonate to be able to dissolve within a reasonable time showing the typical effervescent reaction.
  • metformin hydrochloride being 500 mg to 1000 mg per tablet, the space within the tablet for necessary excipients such as binders, flavours, sweeteners, lubricants and the effervescent couple is quite limited.
  • the present invention may advantageously provide a sodium-free effervescent composition.
  • the sodium carbonate and sodium hydrogen carbonate salts most commonly used for effervescent compositions may not be used in the inventive composition.
  • the reactivities of calcium carbonate and magnesium carbonate are for this kind of composition too low; potassium hydrogen carbonate can cause stability problems, especially if the tablets are packed into aluminium strips. Therefore the preferred carbonate source in the inventive sodium-free composition is potassium carbonate.
  • the following table E shows the carbonate content of the different carbonate salts which are commonly used for the composition of effervescent tablets.
  • the preferred carbonate source (K 2 CO 3 ) for the metformin hydrochloride effervescent tablet is the one with the lowest carbonate content of all commonly used carbonate sources. This fact reduces again the absolute amount of carbonate which is present in the composition.
  • metfomin hydrochloride effervescent tablets must have a composition with an extremely small amount of carbonate.
  • Table F compares a standard effervescent tablet with the requirements of a metformin hydrochloride effervescent tablet in terms of absolute carbonate content:
  • metformin hydrochloride is a substance with very poor tabletting and mixing properties.
  • the substance is very sticky and forms hard and big lumps in the shipping containers. After sieving the material there is a strong tendency of re- agglomeration during the manufacturing process, especially during the mixing process. As a result of this property, an inhomogeneous distribution of the drug in the tablets has been observed even at the high dosed 1000 mg tablets.
  • Such kinds of tabletting and mixing problems are normally solved by performing a granulation of the drug substance together with parts of the citric acid and the carbonate.
  • the granulation process can be done with an aqueous binder solution in a fluid bed granulator or with an alcoholic binder solution in single-pot equipment.
  • Polymers like polyethyleneglycol or polyvinylpyrrolidone are used as binder substances. Due to the agglomeration during the granulation process, the granules normally show improved properties in terms of flowability, stickiness and tabletting properties.
  • Granulation is a costly production step within the manufacturing process of a tablet, and therefore, if it is not necessary, granulation is avoided if possible and the manufacturing of the ready-to-press mixture is performed by a direct mixing process. On the other hand, if any kind of problems occur with the ready-to-press mixture, granulation is the generally accepted and preferred method to overcome those tabletting problems.
  • metformin hydrochloride effervescent tablets it is not possible to overcome drug-related tabletting problems by granulating the drug substance, but direct mixing without any additional steps except sieving and direct compression is the only way to obtain tablets meeting all specification limits.
  • a solution which has been found to improve tabletting properties and tablet hardness without increasing dissolution time is to perform a granulation only of the citric acid anhydrous with one or more compressible binders.
  • the binder is an aqueous solution of a polymer binder such as polyethylene glycol, polyvinlypyrrolidone and their mixtures or an aqueous solution of sorbitol, mannitol and their mixtures.
  • This type of granulation does not modify the critical mixing and tabletting properties of the drug substance but it helps tabletting the whole ready-to-press mixture by improving the tabletting behaviour of the most important excipient which is in the tablet with a percentage of up to nearly 50 %.
  • composition principles can, according to this invention, also be used to prepare powder compositions, or granules containing metformin hydrochloride.
  • powders or granules can be packed into single dose sachets or sticks made from aluminium foil. They can be dissolved in water prior to administration, or they can be taken directly into the mouth.
  • the amount of effervescent couple (acid and carbonate) can be significantly reduced compared to tablet compositions.
  • anti-caking agents such as colloidal silicon dioxide, surface modified silicon dioxide, di-calcium phosphate and so on, in a concentration from about 0.5 % to about 5.0 % is mandatory.
  • Sorbitol has better compression characteristics (more hardness) than mannitol, but is hygroscopic, and can cause sticking on the rotary press. Mannitol is less hygroscopic, but the tablets are not as hard as with sorbitol.
  • the use of mannitol can reduce the negative aspects of sorbitol. It is therefore interesting to use a combination of sorbitol and mannitol, wherein the weight ratio of sorbitol to mannitol is 1 : 1.
  • the mean particle size of the sorbitol to be used is 200 - 400 ⁇ m (microns), preferably about 250 to 300 ⁇ m. In the examples the mean particle size was about 280 ⁇ m.
  • the mean particle size of the mannitol used is about 150 - 300 ⁇ m. In the examples the mean particle size is about 200 ⁇ m.
  • the acid component of the composition can be any suitable acid for effervescent compositions.
  • the acid is an organic or mineral acid that is safe for consumption and which provides effective and rapid effervescent disintegration upon contact with water and the alkaline effervescent compound.
  • the acid may be selected from the group consisting of citric acid, tartaric acid, malic acid, fumaric acid, adipic acid, succinic acid, acid anhydrides and related organic acids.
  • the acid is citric acid, especially anhydrous citric acid, or tartaric acid.
  • an acid salt when used in the composition in place of an acid, it can be any suitable acid salt or any mixture of suitable salts.
  • suitable acid salt include disodium dihydrogen pyrophosphate, acid citrate salts including mono sodium citrate, and other salts of related organic acids.
  • the acid salt is a salt of citric acid or tartaric acid, especially monosodium citrate or monosodium tartarate. If an acid salt is used in the composition, it is preferably used in combination with an acid.
  • the alkaline component can be any suitable alkaline effervescent compound, and typically it is an inorganic base (e.g., an alkali metal carbonate) that is safe for human consumption and provides and effective and rapid effervescent disintegration upon contact with water and the acid compound.
  • the alkaline effervescing compound may be selected from the group consisting of carbonate salts, bicarbonate salts, and mixtures thereof.
  • the alkaline compound is sodium bicarbonate, sodium carbonate anhydrous, potassium carbonate, potassium bicarbonate, magnesium carbonate, sodium glycine carbonate, calcium carbonate, L-lysine carbonate, arginine carbonate, and combinations thereof.
  • the technically preferred alkaline effervescing compounds are sodium bicarbonate, potassium bicarbonate, sodium carbonate, potassium carbonate or mixtures thereof.
  • non-sodium alkaline effervescing compounds may be desirable for patients requiring electrolyte maintenance, such as hypertensive and other cardiac patients receiving ACE inhibitors (angiotensin converting enzyme inhibitor). Therefore the preferred alkaline compounds for the inventive compositions are potassium carbonate and potassium bicarbonate; especially preferred for stability reasons is potassium carbonate.
  • the acid is typically present in an amount of from about 15 % to about 60 % (e.g., about 25% to about 50%) based on the total weight of the composition. For example, about 800 mg to about 2000 mg of acidic compound is present in the effervescent composition.
  • the alkaline effervescent compound is typically present in such an amount that the ratio between acid and carbonate ions is from about 1.5 : 1 to about 3.0 : 1 , preferably 2.0 : 1 to 2.5 :1 based on the total weight of the composition.
  • the weight ratio between the acid and the carbonate ions is greater than 3.0 :1.
  • the preferred weight ratio is about 5.0 :1.
  • a buffer which preferably has a pH of about 2.5 to about 6.5, more preferably about 3.0 to about 5.5.
  • the pH of the specific metformin hydrochloride effervescent composition presented in this invention is within quite narrow limits between about 4.0 and 4.8.
  • An especially preferred pH value is 4.4.
  • the buffer produced upon dissolution of the effervescent composition in water is sufficient to alter the pH of a patient's stomach.
  • the pH of the gastric juice in the stomach of the patient is raised to about 3 or greater, preferably to about 4.
  • the buffer solution typically is capable of mediating the pH of a patient's stomach from 15 to 30 minutes up to about 1 hour.
  • the formulation of the effervescent composition is as follows, in weight % based on the total weight of the composition :
  • component (d) - from 5% to 25% of component (c); - from 5% to 20% of component (d);
  • component (e) being one or more excipient, such as a sweetener, flavorant, colorant, fragrance, anti-caking agent, glidant, etc.
  • the effervescent compositions described above optionally further comprise a sweetener and/or a flavorant.
  • the effervescent composition contains both a sweetener and a flavorant.
  • the sweetener or flavorant is present in an amount of from about 0.1% to about 5% by weight of the total composition.
  • the sweetener can be any suitable natural or artificial sweetener or a combination of natural and artificial sweeteners.
  • Acceptable natural sweeteners include members selected from the group of glucose, dextrose, invert sugar, fructose, glycyrrhizic acid, and mixtures thereof.
  • Acceptable artificial sweeteners include members selected from the group consisting of saccharin; aspartame; chloro derivatives of sucrose such as sucralose, cyclamate, acesulfame-K; sugar alcohols such as sorbitol, mannitol, and xylitol; and mixtures thereof.
  • the sweetener is an artificial sweetener selected from the group consisting of aspartame, saccharin, acesulfame-K, cyclamate, Splenda®, and combinations thereof.
  • the effective concentration of a sweetener is determined by the strength of its sweetness, solubility, and masking ability for a specific active ingredient(s).
  • the sweetener when the sweetener is aspartame, about 10 mg to about 50 mg aspartame is present in the effervescent composition.
  • the sweetener when the sweetener is saccharin, about 10 mg to about 30 mg saccharin is present in the effervescent composition.
  • the sweetener is acesulfame-K, about 10 mg to about 50 mg saccharin is present in the effervescent composition.
  • the sweetener When the sweetener is cyclamate, about 10 mg to about 150 mg cyclamate is present in the effervescent composition.
  • the sweetener is Splenda®, about 10 mg to about 80 mg Splenda® is present in the effervescent composition.
  • the flavorants and sweeteners are not critical for the compression process, but can significantly influence the dissolution time of the effervescent tablets and are important for the taste and odor of the resulting solution once the tables are dissolved.
  • the type and amount chosen should not influence the dissolution time and should mask the bitter taste of metformin hydrochloride.
  • the flavorant can be a natural, a natural-identical or synthetic compound.
  • Acceptable flavorings include members selected from the group consisting of volatile oils, synthetic flavor oils, oleoresins, plant extracts, and combinations thereof.
  • Desirable flavorings include a member selected from the group consisting of citrus oils such as lemon, orange, grape, lime and grapefruit; fruit essences such as apple, pear, peach, grape, strawberry, raspberry, cherry, plum, pineapple, and apricot; and other fruit flavors.
  • flavorants include aldehydes and esters such as benzaldehyde (cherry, almond), citral (lemon, lime), neral (lemon, lime), decanal (orange, lemon), C8- aldehyde (citrus fruits), Cg-aldehyde (citrus fruits), Ci 2 -aldehyde (citrus fruits), tolylaldehyde (cherry, almond), 2,6-dimethyloctanal (green fruit), and 2- dodecenal (citrus, mandarin), and mixtures thereof.
  • the flavorant is lemon, orange or cherry.
  • the flavorant typically is present in the effervescent composition in an amount of about 10 mg to about 150 mg.
  • the effervescent tablet composition comprises 500 to 1000 mg metformin hydrochloride, about 1400 mg to about 2000 mg acid compound in the form of citric acid, about 500 mg to about 1000 mg alkaline effervescing compound in the form of potassium carbonate, about 250 mg to 550 mg binder in the form of sorbitol or mannitol or a mixture thereof, about 0.5% to about 2% sweetener and about 1% to about 5% flavorant.
  • the percent amounts recited above are based on the total weight of the composition.
  • the effervescent compositions described above optionally further comprise a colorant.
  • the colorant can be any suitable colorant including natural colorants, food, drug and cosmetics (FD&C) colorants, and drug and cosmetic (D&C) colorants.
  • FD&C natural colorants
  • D&C drug and cosmetic
  • Suitable natural colorants include red beet powder and beta- carotene powder.
  • the effervescent compositions described above optionally comprise other ingredients to aid in the composition of the composition and/or for aesthetic purposes.
  • Such other ingredients include fragrances, dyes, fillers such lactose, starch, anti-caking agents such as colloidal silicon dioxide, and natural or synthetic polymer binders.
  • Desirable binders assist in tablet compression, and can include starches, pregelatinized starches, gelatin, methylcellulose, sodium carboxymethylcellulose, polyacrylamides, polyvinyloxoazolidone, polyvinylalcohols, polyethylene glycols (e.g. macrogol 6000) and polyvinylpyrrolidone.
  • Effervescent metformin hydrochloride should be administered to the patient following a continuous schedule, generally once, twice or three times daily; generally with tablets containing 500 mg, 850 mg or 1000 mg.
  • the effervescent compositions of the invention have a total weight of 1000 mg or more (e.g., 1500 - 5000 mg).
  • the effervescent tablet compositions have a total weight of about 3500 mg to about 4000 mg.
  • This example illustrates a general process for preparing the effervescent tablets of the invention using sodium hydrogen carbonate as the alkaline compound, using a direct compression process and resulting in a pH of about 3.6.
  • Metformin effervescent tablets 500 mg, 850 mg and 1000 mg were formed from the ingredients listed in Tables 1a et 1 b. Table 1a
  • this compound is sieved through a sieve (e.g. type frewitt) or through a sieve mill (e.g. type co-mill).
  • a sieve e.g. type frewitt
  • a sieve mill e.g. type co-mill
  • metformin hydrochloride is mixed with sodium hydrogen carbonate and with the other compounds except anhydrous citric acid in a container mixer or in another suitable mixer (e.g planetary mixer). This pre-mixture is again sieved and the anhydrous citric acid is added.
  • a container mixer e.g. planetary mixer
  • the ready-to-press mixture is compressed on a suitable tablet press (preferred rotary tablet press) into tablets of 3900 mg weight and with a hardness of about 50 - 90 N.
  • the tablets are packed into tubes with desiccant or into aluminium strips. All production steps are carried out under low humidity conditions, preferably at a relative humidity below 30 %.
  • This example illustrates a more specific process for preparing the sodium-free effervescent tablets of the invention using potassium carbonate as the alkaline compound, using only sorbitol as a dry binder, using a direct compression process and resulting in the preferred pH of about 4.4.
  • Metformin effervescent tablets 500 mg, 850 mg and 1000 mg were formed from the ingredients listed in Tables 2a and 2b.
  • the manufacturing process of the ready-to-press mixture, the tabletting process and the packaging process are the same as for example 1.
  • This example illustrates a specific embodiment of example 2 in which the anhydrous citric acid is granulated with a part of the sorbitol to increase o tablet hardness. Then the tablets are made from the obtained granules and the other ingredients. Additionally this example contains colloidal silicon dioxide as an anti- caking agent. Metformin effervescent tablets (500 mg, 850 mg and 1000 mg) were formed from the ingredients listed in Tables 3a and 3b.
  • Anhydrous citric acid is granulated in a suitable granulator (preferably in a fluid-bed granulator) with an aqueous solution of sorbitol.
  • a suitable granulator preferably in a fluid-bed granulator
  • sorbitol Per tablet about 200 mg of sorbitol are used to prepare the sorbitol solution.
  • this compound is sieved through a sieve (e.g. type frewitt) or through a sieve mill (e.g. type co-mill).
  • metformin hydrochloride is mixed with sodium hydrogen carbonate, with the rest of the sorbitol and with the other compounds except the citric acid granules in a container mixer or in another suitable mixer (e.g planetary mixer). This pre-mixture is again sieved, and the citric acid granules are added. By mixing both compounds (e.g. in a container mixer) the final ready-to-press mixture is obtained.
  • the tabletting process and the packaging process are the same as for example 1.
  • This example illustrates a specific embodiment of the inventive composition in the form of effervescent granules which can be packed into aluminium sachets or into aluminium sticks.
  • the granules can be taken directly in the mouth, or they can be dissolved prior in water to administration.
  • Metformin effervescent granules 500 mg, 850 mg and 1000 mg were formed from the ingredients listed in Tables 4a and 4b.
  • this compound is sieved through a sieve (e.g. type frewitt) or through a sieve mill (e.g. type co-mill).
  • the sieved metformin hydrochloride, the anhydrous citric acid, the sorbitol, the sweetener and a part of the colloidal silicon dioxide are granulated in a suitable granulator (preferably in a fluid-bed granulator) with an aqueous solution of sorbitol. About 200 mg of sorbitol per dose unit are used to prepare the sorbitol solution.
  • the granules are mixed with potassium carbonate and with the remaining excipients in a container mixer or in another suitable mixer (e.g planetary mixer).
  • This ready-to-use mixture is filled into aluminium sacchets or aluminium sticks on a suitable packaging machine.
  • the selection of the excipients is very important for the present direct compression process.
  • the particle size of the components must be adapted to each other to avoid segregation of the components.
  • the blend must display sufficient flow characteristics and sufficient compression characterizes to achieve constant weight and acceptable capacity of the tableting machine.
  • the influence of the excipients correlates directly with the concentration and the physical characteristics of the active ingredient. Metformin hydrochloride is very fine, and has good water solubility; however, it forms very hard and big lumps and its flowability and compression characteristics are insufficient. Therefore the selection of excipients is very important.
  • the compressibility of is not ideal one must add an inert filler to the composition to obtain excellent compression characteristics.
  • sugar or a sugar alcohol for this purpose because they are soluble in water and give a sweet taste.
  • metformin sugar alcohols are preferred because ordinary sugar has an adverse effect on the therapy.
  • Sorbitol in coarse form gives tablets with very good hardness.
  • sorbitol is hygroscopic and tends to stick on the tablet press during tableting, therefore the amount is limited.
  • the compression characteristics of coarse mannitol is not as good as sorbitol, but it is less hygroscopic and has a positive effect on the dissolution and handling of the tableting blend. We found that a mixture of both these sugar alcohols can be superior during compression than the use of sorbitol alone.
  • glidant For the compression of effervescent tablets without any glidant one should granulate most of the excipients, especially the acidic compound. Another possibility is to add a glidant, but the selection of a suitable glidant for effervescent tablets is very difficult. One needs the glidant effect of the lubricant, but it has adverse effects on disintegration of the tablet and increases the disintegration time with increasing concentration. Typical glidants used for normal tablets cannot be used for effervescent tablets because they are not water soluble and give the resulting solution an ugly appearance (film).
  • Lubrication in the present metformin hydrochloride composition can be achieved by the addition of Macrogol 6000 as internal glidant.
  • This material dissolves clearly in water and has excellent glidant effect.
  • the amount of glidant should be 10 mg to 100 mg per tablet.
  • 30 - 59 mg per tablet was suitable for glidant efficiency without adversely effecting disintegration time.
  • the internal lubricants the following substances beside Macrogol 6000 are also suitable: sodium-benzoate, Leucin (micronised), sodiumstearylfumarat (PRUV®).
  • Lubricants for the table press may include hydrophobic compounds such as magnesium stearate, calcium stearate, zinc stearate, polyoxyethylene monostearate, talc, paraffin oil of different viscosity grades, silicon oil of different viscosity grades, light mineral oil of different viscosity grades, and combinations thereof.
  • hydrophobic compounds such as magnesium stearate, calcium stearate, zinc stearate, polyoxyethylene monostearate, talc, paraffin oil of different viscosity grades, silicon oil of different viscosity grades, light mineral oil of different viscosity grades, and combinations thereof.
  • these lubricants do not dissolve in water and can only be used in extremely small quantities. Therefore they are not mixed into the tableting mixture, but are used in the form of external lubricants on the tablet press.
  • the preferred external lubricants are paraffin oil and magnesium stearate, which imparts desirable dissolution characteristics to the tablets and facilitates the highspeed production of the tablets.
  • the tablet mixture is compressed on a suitable commercially available rotary tablet press. If no external lubrication with magnesium stearate is used, the use of polymer layered punches together with an external lubrication of the lower punch with paraffin oil is preferred for tabletting of the mass.
  • the tablets are filled on-line into tubes with desiccant or into aluminium strips.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
EP05789610A 2005-09-22 2005-09-22 Sprudelnde metformin-zusammensetzung und daraus hergestellte tabletten und granulate Withdrawn EP1945190A1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2005/054757 WO2007038979A1 (en) 2005-09-22 2005-09-22 Effervescent metformin composition and tablets and granules made therefrom

Publications (1)

Publication Number Publication Date
EP1945190A1 true EP1945190A1 (de) 2008-07-23

Family

ID=36572108

Family Applications (1)

Application Number Title Priority Date Filing Date
EP05789610A Withdrawn EP1945190A1 (de) 2005-09-22 2005-09-22 Sprudelnde metformin-zusammensetzung und daraus hergestellte tabletten und granulate

Country Status (2)

Country Link
EP (1) EP1945190A1 (de)
WO (1) WO2007038979A1 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
EP1852108A1 (de) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG Zusammensetzungen von DPP-IV-Inhibitoren
CN102838599A (zh) 2006-05-04 2012-12-26 贝林格尔.英格海姆国际有限公司 多晶型
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
PE20091730A1 (es) 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
KR20200118243A (ko) 2008-08-06 2020-10-14 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
NZ599298A (en) 2009-11-27 2014-11-28 Boehringer Ingelheim Int Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
GR1007299B (el) * 2010-03-24 2011-06-06 Uni - Pharma Κλεων Τσετης Φαρμακευτικα Εργαστηρια Αβεε Με Δ.Τ. Uni-Pharma Αβεε, Πρωτοτυπη αναβραζουσα φαρμακευτικη συνθεση υδροχλωρικης μετφορμινης με τη μορφη δισκιου
WO2011138421A1 (en) 2010-05-05 2011-11-10 Boehringer Ingelheim International Gmbh Combination therapy
WO2011154975A2 (en) 2010-06-08 2011-12-15 Cadila Healthcare Limited Pharmaceutical compositions of metformin
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
RU2483717C2 (ru) * 2010-11-22 2013-06-10 Открытое акционерное общество "Химико-фармацевтический комбинат "АКРИХИН" (ОАО "АКРИХИН") Фармацевтическая композиция для лечения диабета (варианты)
WO2013077822A1 (en) * 2011-11-23 2013-05-30 Mahmut Bilgic New formulations for treatment of diabetes
WO2013077824A1 (en) * 2011-11-23 2013-05-30 Mahmut Bilgic Preparation process for a formulation comprising metformin
WO2013077820A1 (en) * 2011-11-23 2013-05-30 Mahmut Bilgic Treatment package composed of dosage forms comprising nateglinide -metformin hydrochloride
US20130303554A1 (en) 2012-05-14 2013-11-14 Boehringer Ingelheim International Gmbh Use of a dpp-4 inhibitor in sirs and/or sepsis
EP3685839A1 (de) 2012-05-14 2020-07-29 Boehringer Ingelheim International GmbH Linagliptin zur verwendung in der behandlung von albuminuria und nierenbedingten erkrankungen
US20140179712A1 (en) * 2012-12-21 2014-06-26 Astrazeneca Ab Pharmaceutical formulation of n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2h-pyrazol-3-yl]-4-[(3r,5s)-3,5-dimethylpiperazin-1-yl]benzamide
CN105407925A (zh) * 2013-03-15 2016-03-16 迈兰公司 用于泡腾剂型的制造工艺
US20160220481A1 (en) * 2013-09-21 2016-08-04 Effrx Pharmaceuticals Sa Low-Sodium Effervescent Pharmaceutical Formulations
CA3018828C (en) 2014-09-17 2021-05-11 Steerlife India Private Limited Effervescent composition and method of making it
EP3359156B1 (de) * 2015-10-07 2022-07-20 Steerlife India Private Limited Schnell zerfallende tablettenzusammensetzungen von dpp-iv-hemmern mit niedrigem mineralgehalt
WO2017098481A1 (en) * 2015-12-12 2017-06-15 Steerlife India Private Limited Effervescent compositions of metformin and processes for preparation thereof
WO2017211979A1 (en) 2016-06-10 2017-12-14 Boehringer Ingelheim International Gmbh Combinations of linagliptin and metformin
TR201914043A1 (tr) * 2019-09-16 2021-04-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Dapagli̇flozi̇n ve metformi̇n i̇çeren efervesan tablet formülasyonlari
CA3179683A1 (en) * 2020-07-15 2022-01-20 Michael Jedwab Compositions to promote swallowing safety and efficiency
US20220160619A1 (en) * 2020-11-25 2022-05-26 Complete Medical Solutions, Llc Effervescent Drug Formulations

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2611500B1 (fr) * 1987-03-06 1990-05-04 Lipha Emploi de derives du biguanide dans la preparation de medicaments
SI0976395T1 (sl) * 1998-07-30 2006-04-30 Merck Sante Sas Tableta s podaljsanim sproscanjem zdravilne ucinkovine v zelodcu
DE19931708A1 (de) * 1999-07-08 2001-01-18 Bayer Ag Verfahren zur Herstellung schnell zerfallender, fester pharmazeutischer Zubereitungen
EP1841414A1 (de) * 2003-12-31 2007-10-10 Alpharma, Inc. Rosiglitazon- und metformin-formulierungen

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2007038979A1 *

Also Published As

Publication number Publication date
WO2007038979A1 (en) 2007-04-12

Similar Documents

Publication Publication Date Title
WO2007038979A1 (en) Effervescent metformin composition and tablets and granules made therefrom
US20200323776A1 (en) Diclofenac formulations and methods of use
RU2493831C2 (ru) Фармацевтические композиции
US6284272B1 (en) Pharmaceutical compositions containing an effervescent acid-base couple
US11219594B2 (en) Effervescent compositions of metformin and processes for preparation thereof
US6667056B2 (en) Pharmaceutical compositions containing an effervescent acid-base couple
JP2003176242A (ja) 速崩壊性圧縮成型物及びその製造法
EP3324947B1 (de) Sprudelnde formulierung von ornithinaspartat
US20100047184A1 (en) Pharmaceutical compositions containing an effervescent acid-base couple
EP4247331B1 (de) Im mund dispergierbare pulverzusammensetzung mit einer antihistaminverbindung
WO2005055971A1 (en) Pharmaceutical effervescent formulation comprising amoxycillin and clavulanic acid
US20160220481A1 (en) Low-Sodium Effervescent Pharmaceutical Formulations
CA2297673C (en) Pharmaceutical compositions containing an effervescent acid-base couple
WO2023031946A1 (en) Effervescent pharmaceutical composition of ascorbic acid and zinc

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20080306

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
RIN1 Information on inventor provided before grant (corrected)

Inventor name: ROEHRICH, TILL

Inventor name: HAEUSLER, FRANZ

GRAC Information related to communication of intention to grant a patent modified

Free format text: ORIGINAL CODE: EPIDOSCIGR1

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20091006